Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 171671 | 3.74 |
09:34 ET | 45322 | 3.76 |
09:36 ET | 9610 | 3.755 |
09:38 ET | 22189 | 3.73 |
09:39 ET | 12974 | 3.725 |
09:41 ET | 15872 | 3.745 |
09:43 ET | 67284 | 3.7312 |
09:45 ET | 55976 | 3.76 |
09:48 ET | 38772 | 3.785 |
09:50 ET | 28318 | 3.7643 |
09:52 ET | 29930 | 3.775 |
09:54 ET | 61770 | 3.77 |
09:56 ET | 15871 | 3.755 |
09:57 ET | 12533 | 3.76 |
09:59 ET | 10014 | 3.751 |
10:01 ET | 12956 | 3.755 |
10:03 ET | 171262 | 3.755 |
10:06 ET | 43358 | 3.745 |
10:08 ET | 24800 | 3.749 |
10:10 ET | 16625 | 3.745 |
10:12 ET | 54575 | 3.715 |
10:14 ET | 8864 | 3.72 |
10:15 ET | 56981 | 3.715 |
10:17 ET | 71628 | 3.75 |
10:19 ET | 4911 | 3.755 |
10:21 ET | 108670 | 3.765 |
10:24 ET | 1133 | 3.76 |
10:26 ET | 1750 | 3.76 |
10:28 ET | 12645 | 3.765 |
10:30 ET | 44837 | 3.755 |
10:32 ET | 10281 | 3.755 |
10:33 ET | 12059 | 3.765 |
10:35 ET | 1280 | 3.765 |
10:37 ET | 43452 | 3.775 |
10:39 ET | 24424 | 3.78 |
10:42 ET | 561852 | 3.805 |
10:44 ET | 7715 | 3.795 |
10:46 ET | 123466 | 3.785 |
10:48 ET | 2644 | 3.79 |
10:50 ET | 116995 | 3.795 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.2B | -11.0x | --- |
Vera Therapeutics Inc | 2.2B | -20.8x | --- |
Rocket Pharmaceuticals Inc | 2.1B | -8.4x | --- |
Keros Therapeutics Inc | 1.9B | -10.6x | --- |
Dyne Therapeutics Inc | 2.5B | -7.4x | --- |
Sana Biotechnology Inc | 1.9B | -5.9x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -11.0x |
Price/Sales (TTM) | 4,197.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.